Mylan, Novartis Settle Spat Over Femara Generic

Law360, New York (December 2, 2008, 12:00 AM EST) -- Novartis Pharmaceutical Corp. has ended its battle with generic-drug maker Mylan Inc. over the patent for the generic version of Novartis' Femara, a drug that treats breast cancer in postmenopausal women, by agreeing to provide Mylan with a license to market the generic before the patent's expiration in 2011.

On Tuesday, Mylan announced that it and its subsidiary Mylan Pharmaceuticals Inc. have entered into an agreement to settle the patent infringement suit lodged by Novartis Pharmaceuticals Corp., Novartis Corp. and Novartis International AG in the U.S....
To view the full article, register now.